29-Jul-2026
Abbott Laboratories: Buy Rating Backed by Strengthening Nutrition Franchise and 2026 Growth Drivers
TipRanks (Wed, 29-Jul 1:45 AM ET)
What's next for Abbott Laboratories after its earnings surprise?
Seeking Alpha News (Tue, 28-Jul 1:00 PM ET)
UBS Issues a Buy Rating on Abbott Laboratories (ABT)
TipRanks (Tue, 28-Jul 8:26 AM ET)
Globe Newswire (Mon, 27-Jul 8:00 AM ET)
Abbott Raises Full-Year EPS Outlook as Diagnostics and Medical Devices Lead Q2 Growth
Market Chameleon (Thu, 16-Jul 7:44 AM ET)
Market Chameleon (Thu, 16-Jul 4:11 AM ET)
Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance
PRNewswire (Thu, 16-Jul 7:30 AM ET)
Abbott hosts conference call for second-quarter earnings
PRNewswire (Thu, 25-Jun 9:01 AM ET)
PRNewswire (Wed, 24-Jun 8:30 AM ET)
PRNewswire (Mon, 22-Jun 12:00 PM ET)
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
Abbott Laboratories trades on the NYSE stock market under the symbol ABT.
As of July 29, 2026, ABT stock price climbed to $108.00 with 9,818,788 million shares trading.
ABT has a beta of -0.30, meaning it tends to be less sensitive to market movements. ABT has a correlation of 0.02 to the broad based SPY ETF.
ABT has a market cap of $188.12 billion. This is considered a Large Cap stock.
Last quarter Abbott Laboratories reported $13 billion in Revenue and $1.31 earnings per share. This beat revenue expectation by $83 million and exceeded earnings estimates by $.03.
In the last 3 years, ABT traded as high as $141.23 and as low as $81.97.
The top ETF exchange traded funds that ABT belongs to (by Net Assets): VTI, SCHD, VOO, IVV, SPY.
ABT has underperformed the market in the last year with a return of -12.6%, while SPY returned +15.7%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in ABT shares. However, ABT has outperformed the market in the last 3 month and 2 week periods, returning +15.7% and +23.0%, while SPY returned +2.8% and -3.0%, respectively. This indicates ABT has been having a stronger performance recently.
ABT support price is $105.27 and resistance is $109.28 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ABT shares will trade within this expected range on the day.